Aquestive Therapeutics (AQST) Return on Sales: 2018-2025
Historic Return on Sales for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to 5.24%.
- Aquestive Therapeutics' Return on Sales rose 584.00% to 5.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.24%, marking a year-over-year increase of 584.00%. This contributed to the annual value of -43.79% for FY2024, which is 4363.00% down from last year.
- Latest data reveals that Aquestive Therapeutics reported Return on Sales of 5.24% as of Q3 2025, which was up 0.13% from 5.24% recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Return on Sales ranged from a high of 23.33% in Q1 2025 and a low of -43.79% during Q4 2024.
- Over the past 3 years, Aquestive Therapeutics' median Return on Sales value was -0.44% (recorded in 2024), while the average stood at -1.21%.
- In the last 5 years, Aquestive Therapeutics' Return on Sales crashed by 4,363bps in 2024 and then soared by 2,389bps in 2025.
- Over the past 5 years, Aquestive Therapeutics' Return on Sales (Quarterly) stood at -2.05% in 2021, then spiked by 77bps to -1.28% in 2022, then surged by 113bps to -0.16% in 2023, then tumbled by 4,363bps to -43.79% in 2024, then skyrocketed by 584bps to 5.24% in 2025.
- Its Return on Sales was 5.24% in Q3 2025, compared to 5.24% in Q2 2025 and 23.33% in Q1 2025.